{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T10:35:40Z","timestamp":1714300540718},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,5,15]]},"DOI":"10.2169\/internalmedicine.6039-20","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T22:09:56Z","timestamp":1608588596000},"page":"1501-1507","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis"],"prefix":"10.2169","volume":"60","author":[{"given":"Ryoji","family":"Tatsumi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sapporo Kosei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Suii","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo Kosei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatsu","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo Kosei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo Kosei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo Kosei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Kuwata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo Kosei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Toyota","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo Kosei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Hige","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sapporo Kosei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60: 715-735, 2014.","DOI":"10.1002\/hep.27210"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Amodio P, Del Piccolo F, Petten\u00f2 E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol 35: 37-45, 2014.","DOI":"10.1016\/S0168-8278(01)00129-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Romero-G\u00f3mez M, Boza F, Garc\u00eda-Valdecasas MS, Garc\u00eda E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 96: 2718-2723, 2001.","DOI":"10.1016\/S0002-9270(01)02692-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44: 217-231, 2006.","DOI":"10.1016\/j.jhep.2005.10.013"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 137: 885-591, 2009.","DOI":"10.1053\/j.gastro.2009.05.056"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362: 1071-1081, 2010.","DOI":"10.1056\/NEJMoa0907893"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328: 1046, 2004.","DOI":"10.1136\/bmj.38048.506134.EE"},{"key":"8","unstructured":"8. De Marco F, Santamaria A, D'arienzo A. Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. Curr Ther Res 36: 668-674, 1984."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Suzuki K, Endo R, Takikawa Y, et al. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: a phase II\/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. Hepatol Res 48: 411-423, 2018.","DOI":"10.1111\/hepr.13045"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Suzuki H, Sezaki H, Suzuki F, et al. Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy. Hepatol Res 49: 1406-1413, 2019.","DOI":"10.1111\/hepr.13415"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"12","unstructured":"12. Umezawa H, Ueda M, Maeda K, et al. Production and isolation of a new antibiotic: kanamycin. J Antibiot (Tokyo) 10: 181-188, 1957."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hewitt WL, Finegold SM. Laboratory studies with kanamycin. Ann N Y Acad Sci 76: 122-128, 1958.","DOI":"10.1111\/j.1749-6632.1958.tb54698.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 12: 203-208, 2000.","DOI":"10.1097\/00042737-200012020-00012"},{"key":"15","unstructured":"15. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammonemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Italian J Gastroenterol 23: 175-178, 1991."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/10\/60_6039-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T04:03:53Z","timestamp":1621051433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/10\/60_6039-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,15]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6039-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,15]]}}}